Estradiol treatment in young postmenopausal women with self-reported cognitive complaints: Effects on cholinergic-mediated cognitive performance

IF 1.8 4区 医学 Q3 CLINICAL NEUROLOGY Human Psychopharmacology: Clinical and Experimental Pub Date : 2022-02-24 DOI:10.1002/hup.2838
Alexander C. Conley, Kimberly M. Albert, Brenna C. McDonald, Andrew J. Saykin, Julie A. Dumas, Paul A. Newhouse
{"title":"Estradiol treatment in young postmenopausal women with self-reported cognitive complaints: Effects on cholinergic-mediated cognitive performance","authors":"Alexander C. Conley,&nbsp;Kimberly M. Albert,&nbsp;Brenna C. McDonald,&nbsp;Andrew J. Saykin,&nbsp;Julie A. Dumas,&nbsp;Paul A. Newhouse","doi":"10.1002/hup.2838","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Objective</h3>\n \n <p>Older women are at increased risk of developing Alzheimer's disease compared to men. One proposed reason is that following menopause there is a decline in estrogens. Estrogens are important for cholinergic functioning and attenuate the impact of cholinergic antagonists on cognitive performance in postmenopausal women. Self-reported or subjective cognitive complaints in middle or older age may represent a harbinger of cognitive decline and those who endorse cognitive complaints appear more likely to develop future cognitive impairment. However, the response of individuals with cognitive complaints after menopause to estrogen and the relationship to cholinergic functioning has not been investigated. This study investigated the effect of estrogen treatment using 17β-estradiol on cognitive performance following anticholinergic blockade in postmenopausal women and the relationship of this interaction with the level of self-reported (subjective) postmenopausal cognitive complaints.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Forty postmenopausal women (aged 50–60 years) completed a 3-month treatment regimen of either 1 mg oral estradiol or placebo. Participants then completed four challenge days in which they completed cognitive and behavioral tasks after one of four cholinergic antagonist drug conditions (oral mecamylamine (MECA), intravenous scopolamine, combined MECA and scopolamine, or PLC).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Compared to PLC, the estradiol treated group performed worse on attention tasks under cholinergic challenge including the choice reaction time task and the critical flicker fusion task. In addition, participants who endorsed greater cognitive complaints showed reduced performance on the N-back working memory task, regardless of whether they received estradiol treatment.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>The findings of this study indicate that estradiol treatment was unable to mitigate anticholinergic blockade in postmenopausal women with subjective cognitive complaints, and worsened performance on attention tasks. Moreover, the present study suggests that greater levels of cognitive complaints following menopause may be associated with an underlying decline in cholinergic function that may manifest as an inability to compensate during working memory tasks.</p>\n </section>\n </div>","PeriodicalId":13030,"journal":{"name":"Human Psychopharmacology: Clinical and Experimental","volume":"37 5","pages":""},"PeriodicalIF":1.8000,"publicationDate":"2022-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Human Psychopharmacology: Clinical and Experimental","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/hup.2838","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Objective

Older women are at increased risk of developing Alzheimer's disease compared to men. One proposed reason is that following menopause there is a decline in estrogens. Estrogens are important for cholinergic functioning and attenuate the impact of cholinergic antagonists on cognitive performance in postmenopausal women. Self-reported or subjective cognitive complaints in middle or older age may represent a harbinger of cognitive decline and those who endorse cognitive complaints appear more likely to develop future cognitive impairment. However, the response of individuals with cognitive complaints after menopause to estrogen and the relationship to cholinergic functioning has not been investigated. This study investigated the effect of estrogen treatment using 17β-estradiol on cognitive performance following anticholinergic blockade in postmenopausal women and the relationship of this interaction with the level of self-reported (subjective) postmenopausal cognitive complaints.

Methods

Forty postmenopausal women (aged 50–60 years) completed a 3-month treatment regimen of either 1 mg oral estradiol or placebo. Participants then completed four challenge days in which they completed cognitive and behavioral tasks after one of four cholinergic antagonist drug conditions (oral mecamylamine (MECA), intravenous scopolamine, combined MECA and scopolamine, or PLC).

Results

Compared to PLC, the estradiol treated group performed worse on attention tasks under cholinergic challenge including the choice reaction time task and the critical flicker fusion task. In addition, participants who endorsed greater cognitive complaints showed reduced performance on the N-back working memory task, regardless of whether they received estradiol treatment.

Conclusions

The findings of this study indicate that estradiol treatment was unable to mitigate anticholinergic blockade in postmenopausal women with subjective cognitive complaints, and worsened performance on attention tasks. Moreover, the present study suggests that greater levels of cognitive complaints following menopause may be associated with an underlying decline in cholinergic function that may manifest as an inability to compensate during working memory tasks.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
雌二醇治疗自我报告认知疾病的年轻绝经后妇女:对胆碱能介导的认知表现的影响
与男性相比,老年女性患阿尔茨海默病的风险增加。一个被提出的原因是绝经后雌激素会下降。雌激素对绝经后妇女的胆碱能功能起重要作用,并减弱胆碱能拮抗剂对认知能力的影响。中老年自我报告的或主观的认知抱怨可能是认知能力下降的先兆,那些认可认知抱怨的人似乎更有可能发展为未来的认知障碍。然而,绝经后有认知障碍的个体对雌激素的反应及其与胆碱能功能的关系尚未被调查。本研究探讨了17β-雌二醇雌激素治疗对绝经后妇女抗胆碱能阻断后认知表现的影响,以及这种相互作用与自我报告(主观)绝经后认知抱怨水平的关系。方法40例绝经后妇女(年龄50 ~ 60岁),分别口服雌二醇1 mg或安慰剂3个月。然后,参与者完成了为期四天的挑战,在四种胆碱能拮抗剂药物条件(口服美甲胺(MECA),静脉注射东莨菪碱,MECA和东莨菪碱联合或PLC)之一后,他们完成了认知和行为任务。结果雌二醇治疗组在选择反应时间任务和关键闪烁融合任务等胆碱能挑战下的注意任务上表现较差。此外,无论是否接受雌二醇治疗,认知抱怨更严重的参与者在N-back工作记忆任务中的表现都有所下降。结论本研究结果表明,雌二醇治疗不能缓解有主观认知障碍的绝经后妇女的抗胆碱能阻滞,并使注意力任务的表现恶化。此外,目前的研究表明,绝经后更严重的认知抱怨可能与潜在的胆碱能功能下降有关,胆碱能功能下降可能表现为在工作记忆任务中无法补偿。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.10
自引率
0.00%
发文量
34
审稿时长
6-12 weeks
期刊介绍: Human Psychopharmacology: Clinical and Experimental provides a forum for the evaluation of clinical and experimental research on both new and established psychotropic medicines. Experimental studies of other centrally active drugs, including herbal products, in clinical, social and psychological contexts, as well as clinical/scientific papers on drugs of abuse and drug dependency will also be considered. While the primary purpose of the Journal is to publish the results of clinical research, the results of animal studies relevant to human psychopharmacology are welcome. The following topics are of special interest to the editors and readers of the Journal: -All aspects of clinical psychopharmacology- Efficacy and safety studies of novel and standard psychotropic drugs- Studies of the adverse effects of psychotropic drugs- Effects of psychotropic drugs on normal physiological processes- Geriatric and paediatric psychopharmacology- Ethical and psychosocial aspects of drug use and misuse- Psychopharmacological aspects of sleep and chronobiology- Neuroimaging and psychoactive drugs- Phytopharmacology and psychoactive substances- Drug treatment of neurological disorders- Mechanisms of action of psychotropic drugs- Ethnopsychopharmacology- Pharmacogenetic aspects of mental illness and drug response- Psychometrics: psychopharmacological methods and experimental design
期刊最新文献
Issue Information Antipsychotic-Treated Schizophrenia Patients Develop Inflammatory and Oxidative Responses Independently From Obesity: However, Metabolic Disturbances Arise From Schizophrenia-Related Obesity Patient outcome following selective serotonin reuptake inhibitor prescribing in primary care in Wales (UK) Issue Information Safety and efficacy of Withania somnifera for anxiety and insomnia: Systematic review and meta-analysis
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1